These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26664153)

  • 1. Erratum: Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids [Corrigendum].
    J Pain Res; 2015; 8():807. PubMed ID: 26664153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids.
    Ueberall MA; Mueller-Schwefe GH
    J Pain Res; 2015; 8():459-75. PubMed ID: 26300655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum: Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum].
    J Pain Res; 2018; 11():1163. PubMed ID: 29950887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum.
    Paediatr Child Health; 2015; 20(8):466-7. PubMed ID: 26744561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
    Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
    Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum: Ignoring the sacroiliac joint in chronic low back pain is costly [Corrigendum].
    Clinicoecon Outcomes Res; 2016; 8():349. PubMed ID: 27462172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical features of opioid-induced constipation in the general population: A French study of 15,000 individuals.
    Ducrotté P; Milce J; Soufflet C; Fabry C
    United European Gastroenterol J; 2017 Jun; 5(4):588-600. PubMed ID: 28588891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum: Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum].
    Neuropsychiatr Dis Treat; 2015; 11():863. PubMed ID: 25848284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum: BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum].
    Breast Cancer (Dove Med Press); 2015; 7():163. PubMed ID: 26170717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erratum: Risk of respiratory depression with opioids and concomitant gabapentinoids [Corrigendum].
    J Pain Res; 2018; 11():1877. PubMed ID: 30271193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicians Experience with and Expectations of the Safety and Tolerability of WHO-Step III Opioids for Chronic (Low) Back Pain: Post Hoc Analysis of Data from a German Cross-Sectional Physician Survey.
    Ueberall MA; Eberhardt A; Mueller-Schwefe GH
    Pain Res Treat; 2015; 2015():745048. PubMed ID: 26568890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system.
    Silverman S; Raffa RB; Cataldo MJ; Kwarcinski M; Ripa SR
    J Pain Res; 2017; 10():1255-1263. PubMed ID: 28579823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.
    Guerriero F; Roberto A; Greco MT; Sgarlata C; Rollone M; Corli O
    Drug Des Devel Ther; 2016; 10():1515-23. PubMed ID: 27143857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.
    Koopmans-Klein G; Van Op den Bosch J; van Megen Y; Prenen H; Huygen F; Mancini I
    Curr Med Res Opin; 2017 Dec; 33(12):2217-2227. PubMed ID: 28805471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
    Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
    Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
    Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
    J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
    van Dongen VC; Vanelderen PJ; Koopmans-Klein G; van Megen YJ; Van Zundert J; Huygen FJ
    Int J Clin Pract; 2014 Nov; 68(11):1364-75. PubMed ID: 24853258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.